Recently, using massively parallel sequencing, stabilizing mutations in NOTCH1 were identified in CLL, 4 and preliminary associations of NOTCH1 mutations and CLL disease characteristics were reported. The latter included detection of an enrichment of NOTCH1 mutations in IgV H unmutated CLL, results indicating worse overall survival (OS) and an association of NOTCH1 exon 34 mutations with disease transformation (Richter's transformation). 5 To complement existing knowledge of the frequency, characteristics and clinical impact of NOTCH1 exon 34 mutations in CLL, and to provide guidance for future research, we resequenced NOTCH1 exon 34 in a well-characterized, prospectively enrolled cohort of 257 CLL patients, of which 200 were untreated and 57 relapsed at study enrollment. 6 Sequence analysis using Sanger sequencing was performed on DNA isolated from FACS-sorted CD19 þ cells, cryopreserved at the time of study enrollment. The somatic nature of mutations was confirmed using paired DNA isolated from FACS-sorted CD3 þ cells.
A total of 21 NOTCH1 exon 34-mutated cases were identified, resulting in a mutation frequency estimate of 8% in this cohort. Data are summarized in Table 1 . We identified 18 cases with NOTCH1 exon 34 frameshift mutations, the majority (13/21 ¼ 62%) of which displayed the reported hotspot dinucleotide deletion (c.7541_7542het_delCT), and 3 cases with nonsense mutations. Interestingly, NOTCH1 exon 34 mutations were substantially enriched in CLL samples that were relapsed at enrollment (10/57 ¼ 18%), whereas the frequency in untreated CLL was substantially lower (11/200 ¼ 6%).
Next, we reviewed in detail the characteristics of the 21 CLL cases with NOTCH1 exon 34 mutations. CLL with NOTCH1 exon 34 mutations were highly enriched for IgV H unmutated status (18/ 21 ¼ 86%), ZAP70 positivity 420% (19/21 ¼ 90%) and CD38 positivity 430% (12/20 ¼ 60%), indicating strong co-occurrence with biological traits associated with progressive and proliferative CLL (see Table 1 ).
In contrast to these very strong associations, NOTCH1 exon 34-mutated CLL was rarely associated with del17p (1/21 ¼ 5%), Letters to the Editor and was associated with TP53 mutations (3/21 ¼ 14%) or del11q (5/21 ¼ 24%) at frequencies expected for random associations. However, trisomy 12 was detected at frequencies that were substantially higher than expected (11/21 ¼ 52%), possibly indicating cooperation between these two genomic aberrations.
We also analyzed SNP 6.0 array-based acquired subchromosomal copy number aberrations (aCNA) in CLL with NOTCH1 exon 34 mutations (SNP 6.0 arrays, Affymetrix, Santa Clara, CA, USA). Data, summarized in Table 1 , indicate that most such cases had relatively stable genomes (X2 aCNA was found in 5/21 ¼ 24%: a frequency similar to those identified in the entire cohort). 6 The aforementioned data suggested to us that NOTCH1 exon 34 mutations as detected through direct sequencing occurred late in CLL disease evolution and usually in the setting of known factors associated with proliferative and progressive CLL, but at frequencies suggesting random association with genomically high-risk CLL (which is aggressive CLL with short OS; here it is defined as the presence of either del17p, del11q, elevated single-nucleotide polymorphism array-based aCNA count or TP53 mutations).
Next, we determined effects of NOTCH1 exon 34 mutations on outcome in CLL, restricting the analysis to the CLL cohort that was untreated at the date of trial enrollment and using the trial enrollment date (equal to the sample procurement date) as the reference date for analysis. We performed multivariate analysis based on proportional hazard modeling, using OS as the primary endpoint and incorporating variables known to affect the clinical course of CLL patients. Data are summarized in Table 2 (data for the modeling using the CLL diagnosis date as a reference is included in Table 2 , right columns). From this data, known strong predictors of short OS in CLL, including TP53 mutations, del17p, or elevated single-nucleotide polymorphism arraybased genomic complexity, emerged with substantially elevated hazard ratios, whereas NOTCH1 exon 34 mutations did not emerge as either strong or significant predictors (all hazard ratios close to 1, P-values not significant).
Finally, given the reported association of NOTCH1 exon 34 mutations with Richter's transformation, we assessed the 21 cases with NOTCH1 exon 34 mutations in our cohort for such an event. Overall, we identified three cases with disease transformation (one patient with secondary Hodgkin's lymphoma following prior therapies for CLL and two cases of large B-cell lymphoma) that resulted in the deaths of these patients. The frequency of disease transformation in this cohort of 21 NOTCH1 exon 34-mutated CLL was 3/21 ¼ 14%.
In summary, our data provide important confirmatory data on the frequency of NOTCH1 exon 34 mutations in CLL. We provide novel detailed insights into the association of NOTCH1 exon 34-mutated CLL with biological markers and describe strong associations with proliferative CLL, but fail to confirm associations with survival. However, given the relatively low frequency of NOTCH1 exon 34 mutations in untreated CLL, much larger studies are needed to confirm these findings. Future work on CLL with NOTCH1 exon 34 mutations likely will focus on the role of mutated NOTCH1 in CLL cell proliferation or survival and testing NOTCH1 exon 34 mutations as a novel target for NOTCH --NOTCH ligand axis-directed therapeutics. Myelodysplastic syndromes (MDS) are defined as clonal disorders of haematopoietic stem/progenitor cells (HSPCs), characterized by ineffective haematopoiesis, peripheral blood cytopenia, morphologic dysplasia and susceptibility to acute myeloid leukemia (AML).
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Although cytogenetic abnormalities can be identified in about half the cases of MDS, 3 relatively little is known about the genetic basis of MDS. The t(3;5)(q25;q34) translocation, creating the NPM-MLF1 fusion, has been found as a sole cytogenetic abnormality in MDS/ AML patients. 4 The nucleophosmin1 (NPM1) gene, located on 5q35, encodes a protein that takes part in a diversity of biological processes such as centrosome duplication, genomic stability and ribosome biogenesis. 5 In MDS/AML patients with t(3;5), inactivation of one functional NPM allele resulting from the t(3;5)(q25;q34) translocation may be a key event in disease development. This concept is supported by the observations that Npm þ /À mice exhibit some of the disease phenotypes resembling human MDS, 6 and show predisposition to leukaemia.
7 Therefore, we postulate that in patients, reduction in the expression levels of wild-type NPM1 is essential for the induction of MDS by NPM-MLF1.
In this report, we show that wild-type NPM and NPM-MLF1 physically interact. Reducing wild-type NPM levels enabled NPM-MLF1 to enhance the colony-forming activity of myeloid HPCs during a prolonged period of liquid culture. This was accompanied by concomitant increased expression of Hoxa9/10 and Meis1 genes, an important measure of the oncogenic potential of myeloid progenitors.
8 --10 Our data demonstrate that Npm haploinsufficiency is critical for NPM-MLF1 to enhance myeloid progenitor activity, essential for the initiation of MDS.
A key feature of the NPM-MLF1 fusion gene is that it retains the homo-dimerization domain of NPM. This suggests that wild-type NPM may be capable of interaction with the NPM-MLF1 fusion protein. To test this hypothesis we performed immunoprecipitations of cell lysates from NPM-MLF1-expressing mouse NIH-3T3 fibroblasts. Total cell lysates were immunoprecipitated with an antibody against the C-terminus of NPM (a moiety not present in the NPM-MLF1 fusion) or with an IgG1-k antibody as an isotype control, and immunoblotted with FLAG antibody to detect the presence of co-precipitated NPM-MLF1 fusion protein. As seen in Figure 1a , a protein of approximately 56 kDa corresponding to the FLAG-tagged fusion protein was detected in the total cell lysate (lane 3) and in the precipitated NPM complex (lane 6), but not in control cell lysates. The physical interaction between NPM-MLF1 and endogenous NPM was further confirmed using an anti-FLAG antibody to precipitate the NPM-MLF1 protein, followed by immunoblotting with the anti-NPM antibody. The 40-kDa NPM protein was detected in the NPM-MLF1 immunoprecipitates (lane 6, Figure 1b) . As high levels of NPM protein were still present following immunodepletion with the FLAG antibody, this suggests that only a proportion of endogenous NPM interacts with NPM-MLF1 (lanes 10 --12). Hence, it is possible that the effect of NPM-MLF1 may be masked by relatively high-abundance NPM in normal HPCs, suggesting a crucial role of NPM haploinsufficiency in NPM-MLF1-associated pathogenesis. 
